Achieving Localised Delivery With Magnetic Vectoring - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Achieving Localised Delivery With Magnetic Vectoring
Charles E. Seeney tells us about the possibilities of nanotechnology and magnetism, and how a novel approach could improve localised drug delivery.


Pharmaceutical Technology Europe


References

1. Magnetism in Medicine: A Handbook, Wilfried Andrä and Hannes Nowak, Eds. (Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 2nd ed., 2007).

2. M.N. Faddis et al., Circulation 106(23), 2980–2985 (2002).

3. M. Baumann et al., Rofo 178(9), 911–917 (2006).

4. J. Klostergaard et al, Future Medicines: Nanomedicine (In press, 2012).

5. R. Bawa, Nanotechnology Law and Business 5, 135–155 (2008).

6. S. Laurent S and M. Mahmoudi, Int. J. Mol. Epidemiol. Genet. 2(4), 367–390 (2011).

7. J. Klostergaard et al., AIP Conference Proceedings (Germany, 2010) pp. 382–387

8. J. Klostergaard et al., J. Magnetism Magnetic Materials 311(1) (2007).

9. C. Plank et al., Expert Opin. Biol. Ther. 3(5), 745–758 (2003).

10. M. Johannsen et al., Int. J. Hyperthermia 21(7), 637–747 (2005).

11. C.E. Seeney et al., Biomaterials, 26(14), (2005).

12. P.Y. Chen et al., Neuro Oncol. 12(10), 1050–60 (2010).

13. M.Y. Hua et al., Biomaterials 32(2), 516–27 (2011).

14. G. Lian et al., Microsc Microanal 10, Suppl. 2 (2004).

15. M. Ma, A: Physicochem. Eng. Aspects 212, 219–226 (2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
42%
No government involvement in patient treatment or drug development.
12%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here